Special Issue "United in the Prevention of Bacterial Resistance during the COVID-19 Era"
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: 30 November 2022 | Viewed by 385
Interests: systemic infections; antibiotic resistance; CNS infections; viral hepatitis
Interests: antibiotic resistance; severe infections; rare infections
Interests: antibiotic resistance and new therapies; sepsis; emergent diseases; tropical imported diseases
Special Issues, Collections and Topics in MDPI journals
The antimicrobial resistance (AMR) is inducing an increasingly significant burden on public health, this issue becoming even more pronounced in the context of COVID-19 pandemic. The infection with SARS-CoV 2, until recently an absolutely unknown element in the landscape of infectious pathology, created from the very beginning the premises of fear both in general population and among healthcare personnel, an aspect which led to a further attitude of overprotection. Subsequently, a systematic, early, and often non-judicious administration of antibiotics has been observed, even in the absence of any data attesting to a co-infection. An eventual later development of a true superinfection often necessitated therapy escalation or an extension of the administration period of the initial antibiotic regimen.
Last, but not least, it is worrisome that the dramatic increase in misuse or overuse of reserve antibiotics, with difficult to quantify consequences concerning the resistance patterns of certain germs or the mortality rates associated with these infections.
The main purpose of this Special Issue is to provide an appropriate background for sharing with us your experience gained during the COVID-19 pandemic period, so that the data provided could enhance the therapeutic management and optimize the antibiotic regimens in all services where infectious pathologies are a constant of daily clinical practice. Therefore, original research and reviews from interdisciplinary areas focusing on antibiotic therapy and antibiotic resistance related to COVID-19 will be of great interest.
Prof. Dr. Egidia Gabriela Miftode
Prof. Dr. Gabriel Adrian Popescu
Dr. Simin-Aysel Florescu
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Coronavirus disease 2019
- antimicrobial resistance
- antimicrobial treatment
- antimicrobial development